Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cannabis-Like drugs may unlock diabetes secrets

NCT ID NCT01517100

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 09, 2026 · Updated 12 times

Summary

This study tested two drugs that act on the body's endocannabinoid system—nabilone and CP-945,598—to see how they affect insulin production and sensitivity. Forty-five healthy men aged 21 to 55 took part in four visits, each receiving a different drug combination. The goal was to better understand how this system regulates insulin, which could lead to new diabetes treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Nabilone and CP-945,598
What this could lead to
If successful, this could point toward new treatment approaches for type 2 diabetes by targeting the endocannabinoid system.
What could go wrong
This is a small, early-phase study in healthy men, not people with diabetes. Results may not translate to real-world treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

45 people

The number who actually took part.

Start date

Jan 2012

Finished

Oct 2014

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION CRITERIA: 1. Healthy men only (We want to study men because the magnitude of acute insulin response for men and women is different. In addition, as women may become pregnant in the course of the study, and since this is a physiology study only, and not one related to treatments, we want to remove any confounders and lessen any chance of drop-out.) 2. Age 21-55 (Age restriction is used to remove age as a confounding factor because Beta cells function tends to deteriorate and first phase secretion becomes less defined with age. 3. Screening laboratory evaluations with no clinically significant abnormal results (minor deviations from normal lab results will be at the discretion of the principal investigator): 1. fasting comprehensive metabolic panel 2. complete blood count with differential and platelet 3. thyroid function test (TSH, free T4) 4. urinalysis 5. urine drug screen 4. BMI less than 30 (Men with BMI greater than or equal to 30 are excluded because obesity has been associated with altered beta cell function. 5. Have NOT participated in another clinical trial involving any pharmacologic agents within the past 30 days 6. Able to complete an inform consent 7. Agree to not participate in other clinical trials within the study period (at the discretion of the study investigator) EXCLUSION CRITERIA: 1. Women 2. FPG greater than or equal to 100 mg/dl or 2-hr OGTT greater than or equal to 140 mg/dL 3. Evidence of illicit drug use 4. History of substance abuse including marijuana within the past 6 months 5. History of smoking any tobacco products within six months prior to screening 6. Alcohol intake greater than 30 grams (drink more than 2 beers per day OR equivalent amount of alcohol) 7. History of Human Immunodeficiency Virus (HIV) infection 8. History of active or chronic Hepatitis B and/or C infection 9. History of malignancy 10. History of coronary disease 11. History of seizures or other neurologic diseases 12. History of psychiatric illnesses including major depressive disorder, schizophrenia, bipolar disorder 13. Any lifetime history of suicide attempt 14. History of suicidal behavior in the last year 15. Any suicidal behavior during any follow-up visits 16. History of any suicidal ideation of type 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) in the last year 17. Any suicidal ideation of type 4 or 5 on the C-SSRS during any follow-up visits. 18. Patient Health Questionnaire-9 (PHQ-9) score greater than or equal to 10 during screening visit or any follow-up study visits 19. Generalized Anxiety Disorder-7 (GAD-7) score greater than or equal to 10 during screening visit or any follow-up visits 20. History of liver or renal diseases 21. History of gastrointestinal or endocrine disorders 22. History of glucocorticoid use (over one month) or other immunosuppressive agents (any) 23. Any condition or non-removable device contraindicated for MRI (pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips, metallic prostheses, permanent eyeliner, implanted delivery pump, or shrapnel fragments, or history of working as a welders or metal worker) 24. Any medical history that, in the opinion of the investigator(s), will make participation of the subject in the study unsafe

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy volunteers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Insulin Resistance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Institute of Aging, Clinical Research Unit

    Baltimore, Maryland, 21224, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.